Monday, May 13, 2013

• FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia ABusiness Wire( (Mon, May 13)

Thursday, April 25, 2013

• Biogen Idec Total Revenues Increased 10% to $1.4 Billion in First Quarter 2013Business Wire( (Thu, Apr 25)

Wednesday, April 10, 2013

• Biogen Idec to Report First Quarter 2013 Financial Results on April 25, 2013Business Wire( (Wed, Apr 10)

Thursday, April 4, 2013

• The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of Daclizumab HYP in Multiple SclerosisBusiness Wire( (Thu, Apr 4)

Tuesday, April 2, 2013

• Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI®Business Wire( (Tue, Apr 2)

Wednesday, March 27, 2013

• Biogen Idec’s TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple SclerosisBusiness Wire( (Wed, Mar 27)

Friday, March 22, 2013

• CHMP Issues Positive Opinion for TECFIDERA™ (Dimethyl Fumarate) as a First-Line Treatment for Multiple Sclerosis in the European UnionBusiness Wire( (Fri, Mar 22)

Wednesday, March 20, 2013

• Positive Year One Results from Biogen Idec Phase 3 ADVANCE Trial of PLEGRIDY™ (Peginterferon Beta-1a) Presented at AAN MeetingBusiness Wire( (Wed, Mar 20)

Tuesday, March 19, 2013

• US Patent Office Grants Patent Claiming Dosing Regimen for TECFIDERA™ (Dimethyl Fumarate)Business Wire( (Tue, Mar 19)

Monday, March 18, 2013

• ADDING MULTIMEDIA New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody StatusBusiness Wire( (Mon, Mar 18)

Tuesday, March 12, 2013

• Biogen Idec Submits Application to FDA for First Long-Lasting Factor VIII Therapy for Hemophilia ABusiness Wire( (Tue, Mar 12)

Wednesday, March 6, 2013

• Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN Annual MeetingBusiness Wire( (Wed, Mar 6)

Monday, March 4, 2013

• FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia BBusiness Wire( (Mon, Mar 4)